1 / 16

Office of Generic Drugs Research Program

Office of Generic Drugs Research Program. Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, Oct. 22, 2003. Definition of a Generic Drug. Approved Generic Products are Therapeutically Equivalent to a Reference Listed Drug

tab
Download Presentation

Office of Generic Drugs Research Program

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Office of Generic DrugsResearch Program Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, Oct. 22, 2003

  2. Definition of a Generic Drug • Approved Generic Products areTherapeutically Equivalent to a Reference Listed Drug • Interchangeable with the reference drug • Same active ingredient, same dosage form, same route of administration, and identical in strength/concentration • Same clinical and safety profile when administered according to the label • Comparable in quality with the reference drug

  3. Therapeutic Equivalence FDA considers products to be therapeutically equivalent if they are: • Pharmaceutical Equivalents • Same active ingredient, dosage form, route of administration, strength/concentration, purity, quality • Same clinical and safety profiles; Bioequivalent • the rate and extent of absorption are not significantly different when administered at the same molar dose under similar experimental conditions • Adequately Labeled • Manufactured according to cGMP

  4. Systemic Drugs • Bioequivalence methods well established • OGD Efficiency • 373 approval actions in FY 2003 • Still some scientific challenges

  5. Locally Acting Drugs Plasma concentration is usually not relevant to bioequivalence • 21 CFR 320.24 allows alternatives: • in vivo pharmacodynamics • in vivo clinical comparisons • in vitro comparisons • other appropriate approaches Need for OGD Research Program

  6. OGD Research Program • Respond to scientific challenges in ANDAs • Polymorphism • Impurities • Complex Drug Products • Endogenous Drug Products • Scientific basis for generic products, e.g. • Topical • Nasal • Inhalation • Liposomes

  7. Polymorphism • Scientific symposium on polymorphism, June 7, 2002 • FDA ACPS support, October 21-22, 2002 • GPhA/OGD joint meeting, February 6, 2003 • CMC CC review, March 19, 2003 • Scientific Considerations • Pharm. Res., April, 2003 • Adv. Drug Del. Rev., December 2003/January 2004 • Guidance to be issued

  8. Impurities • Working Group Formation, March 27, 2003 • To propose recommendations for ANDAs on identification, qualification, and establishment of specifications for drug substance and drug product Impurities • GPhA Technical Advisory Meeting, Jun. 11, 2003 • OGD/GPhA joint meeting, Sep. 24, 2003 • GPhA Fall Technical Conference, Oct.16, 2003 • Guidance to be issued

  9. Complex Drug Substances • Low molecular weight heparin (LMWH) • Product contains a distribution of molecular species • Pharmaceutical equivalence requires the “same” active ingredient • Developed criteria to evaluate claims that two LMWH products contain the same active ingredient

  10. Endogenous Drug Products • The Challenge • If the drug substance is present in the body naturally, then bioequivalence based on total plasma concentration may not be sufficient • Evaluate BE methods • Baseline correction methods • Role of feedback control • Pharmacokinetic/pharmacodynamic modeling

  11. Key Scientific Challenge • Bioequivalence of locally acting drugs • Examples • Topical • Nasal Spray Suspensions • Inhalation • Current FDA guidance may require clinical testing • Target research to provide a scientific basis for in vitro or in vivo bioequivalence methods

  12. Nasal and Inhalation Product BE • Nasal and Inhalation BEs • Nasal BE - Draft guidance (revised 2003) • In vitro BE methods for nasal spray solutions • BE methods for nasal spray suspensions; Clinical Testing • Inhalation BE - No guidance • Received several controlled correspondences • Sept 2003 Symposium: Pharmaceutical aerosols and sprays

  13. Topical Products • In Vitro/In Vivo Methods • Explore various approaches to develop methods to determine BE of topical products • Formulation/Manufacturing Process Characterization (Q3)1 • Dermatopharmacokinetics (DPK) 1 Jonathan Wilkin, ACPS, March 12, 2003

  14. Development of Q3 Concept • In vitro methods to assess structural similarity of topical products • Q1: Qualitative similarity in composition • Q2: Quantitative similarity in composition • Q3: Structural similarity • Describe the physical attributes and state of the product • Reflect changes in manufacturing or physical state of starting materials

  15. DPK: Improvement of Methodology • Objectives • Develop and demonstrate an improved skin stripping methodology for studying dermatopharmacokinetics of topical products in the stratum corneum of human subjects in vivo • Provide the basis for a new/revised bioequivalence guidance for topical anti-fungal products

  16. Bioequivalence of Topical Products OGD Research Program Lawrence Yu, Ph.D. Dermatopharmacokinetics Annette Bunge, Ph.D. Bioequivalence of Topical Products Jonathan Wilkin, M.D. Q& A

More Related